Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications

P Genereux, Stuart Head, DA Wood, SK Kodali, MR Williams, JM Paradis, M Spaziano, Arie-Pieter Kappetein, JG Webb, A Cribier, MB Leon

Research output: Contribution to journalArticleAcademicpeer-review

122 Citations (Scopus)


Surgical aortic valve replacement (SAVR) is currently the standard of care to treat patients with severe symptomatic aortic stenosis (AS) and is generally accepted to alleviate symptoms and prolong survival. Based on the results of randomized trials, transcatheter aortic valve implantation (TAVI) is the new standard of care for patients with symptomatic AS who are deemed oinoperable'. Debatably, TAVI is also an alternative to SAVR in selected patients who are at high risk but operable. As we approach 10 years of clinical experience with TAVI, with over 50 000 implantations in 40 countries, a review of the current literature and clinical outcomes with this rapidly evolving technology is appropriate.
Original languageUndefined/Unknown
Pages (from-to)2388-+
JournalEuropean Heart Journal
Issue number19
Publication statusPublished - 2012

Research programs

  • EMC COEUR-09

Cite this